Syros Pharmaceuticals, Inc. (SYRS)
SYRS Chart as of 2025-03-11
Stock Information
| CEO: | – |
| CFO: | – |
| Employees: | 68 |
| Address: | 35 CambridgePark Drive, Cambridge, MA, United States |
| Country: | United States |
| Website: | https://www.syros.com |
| Listing Date: | – |
| Founded: | – |
| Founder: | – |
| Current Price: | 0.13600000739097595 USD |
| Today Change: | -9.33% |
| Outstanding Shares: | 26,832,500 |
| Volume: | 691,165,698 |
| Avg Volume: | 3,593,706 |
| Expert Target Price: | 8.7500 (Institutions: 0) |
| EPS: | – |
| PER: | – |
| Dividend Date: | – |
| Last Split Date: | 2022-09-19 |
| Last Split Factor: | 1:10 |
Key Executives
| Name | Title | Pay | Year |
|---|---|---|---|
| Dr. James E. Bradner M.D. | Founder | — | — |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder & Member of Scientific Advisory Board | — | — |
| Matthew Foster | Chief Restructuring Officer | — | — |
Financials
Income Statement
| Metric | Amount |
|---|---|
| Total Revenue | 9,936,000 |
| Cost Of Revenue | – |
| Gross Profit | – |
| Operating Income | -126,499,000 |
| Net Income | -164,574,000 |
Balance Sheet
| Metric | Amount |
|---|---|
| Total Assets | 168,174,000 |
| Total Liabilities | – |
| Total Stockholder Equity | – |
Cash Flow
| Metric | Amount |
|---|---|
| Total Cash From Operating Activities | – |
| Capital Expenditures | – |
SEC Filings (Gemini Summaries)
| AccNo | Date | Summary |
|---|---|---|
| 0001972362-25-000274 | 2025-03-11 | Form 144 filing: Peter Wirth, a Syros Pharmaceuticals director, plans to sell 9,333 shares of common stock on NASDAQ (est. value $2007.53) through Morgan Stanley, acquired via restricted stock grants as compensation. No sales in the past 3 months. |
| 0001193125-25-050928 | 2025-03-10 | Syros Pharmaceuticals files post-effective amendments to S-8 registration statements to deregister unsold common stock under multiple equity incentive and stock purchase plans. Filing date: March 10, 2025. |
| 0001193125-25-050923 | 2025-03-10 | Syros Pharma files S-8 post-effective amendments to deregister unsold common stock under multiple registration statements (333-212363, etc.) related to their equity incentive plans and employee stock purchase plans. Filed March 10, 2025. |
| 0001193125-25-050918 | 2025-03-10 | Syros Pharma files a post-effective amendment to Form S-8 to deregister unsold common stock shares from multiple registration statements (Nos. 333-212363 through 333-281118) related to equity incentive and employee stock purchase plans. Filed March 10, 2025. |
| 0001193125-25-050913 | 2025-03-10 | Syros Pharma files a Post-Effective Amendment to Form S-8, deregistering unsold common stock from multiple registration statements (333-212363, 333-216821, etc.) related to equity incentive plans and employee stock purchase plans. Filed March 10, 2025. |
News Summary
– StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)
2025-02-25 07:14:43 | ETF Daily News
stock analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) on Tuesday. The brokerage set a “sell” rating on the stock.
Link
– Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com
2025-02-11 06:13:09 | ETF Daily News
StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell’ rating on the stock.
Link
– Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com
2025-02-18 06:44:52 | ETF Daily News
StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.
Link
– Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33
2025-02-26 06:56:47 | ETF Daily News
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given a consensus rating of “Hold” by the five research firms that are presently covering the firm. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company.
Link
Analysis of Today’s Move
Syros Pharmaceuticals (SYRS) stock likely fell today due to a combination of factors. Recent analyst coverage initiating a “sell” rating has dampened investor sentiment. StockNews.com issued multiple reports with this negative outlook. This likely influenced market perception of the stock.
Furthermore, a director’s planned sale of shares also contributed. Peter Wirth, a Syros Pharmaceuticals director, filed Form 144. This form indicated his intention to sell 9,333 shares. This proposed sale, though relatively small, can signal a lack of confidence. Insider selling activity is often viewed negatively by investors.
The deregistration of unsold shares adds another layer. Syros filed multiple post-effective amendments to Form S-8. These filings deregistered unsold common stock from employee plans. This action could signal less demand for these employee stock programs. It may also indicate a need to streamline existing stock offerings.
While a consensus “hold” rating and a price target of $3.33 exist, the negative news outweighed this. The “sell” rating from StockNews.com has more immediate impact. Insider selling also creates uncertainty amongst investors. Therefore, the combined effect of these events drove the stock price down.
This stock has shown a change of -9.33% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.
The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.
Leave a Reply